Advertisement

Advertisement

News

Can Novel Intratumoral Injection Convert Early-Stage Breast Cancers Into Immunogenic Tumors?

News

Treatment With Tisagenlecleucel for Infants and Toddlers With B-Cell ALL

News

AASLD 2022: Targeting Claudin-1 With a Monoclonal Antibody in Cholangiocarcinoma

News

SITC 2022: Immunity Hubs and Response to Immunotherapy in NSCLC

Medical Literature

Consider the Intestinal Environment in Predicting Immunotherapy Response in Liver Cancer

News

Tisagenlecleucel Infusion in Lymphoma: Focus on Coagulation and Fibrinolytic Parameters

News

SOHO 2022: How Does CAR T-Cell Therapy Measure Up to ASCT in Advanced DLBCL?

Adam D. Cohen, MD, on Multiple Myeloma: Findings on CART-BCMA Infusions

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Administering Daratumumab

View More

Advertisement

JNCCN Spotlights

(UPDATE) Daratumumab (MM)

(UPDATE) Pembrolizumab (NSCLC)

Elotuzumab

View More

More

News

SITC 2022: Is Immunotherapy Feasible for Patients Living With HIV and NSCLC?

MRD-Driven, Time-Limited Triplet Therapy Under Study in CLL

Can Novel Intratumoral Injection Convert Early-Stage Breast Cancers Into Immunogenic Tumors?

Second-Line Combination Chemotherapy Under Study in Biliary Tract Cancer

SOHO 2022: Clinical Overview of CD20/CD3 Bispecific Antibodies in B-Cell Lymphoma

Tisagenlecleucel Infusion in Lymphoma: Focus on Coagulation and Fibrinolytic Parameters

SITC 2022: Phase II Study of Vudalimab for Metastatic Castration-Resistant Prostate Cancer

AASLD 2022: Targeting Claudin-1 With a Monoclonal Antibody in Cholangiocarcinoma

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

Exploring the Current and Future Role of BCMA-Directed Therapy in the Management of Multiple Myeloma

Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

View More

Available

Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials

Center for Immunotherapy Clinical Research Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

ClinicalTrials.gov Immunotherapy

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.